Midline-shift mean absolute error
0.7 mm
- EndpointDifference from three-expert reference midline shift
- Population153 adult NCCT cases, 13 sites, age 26-93
- Tested versionRapid MLS in K243378; release number not stated
FDA-cleared profile
iSchemaview Inc. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: Brain midline-shift measurement on adult non-contrast CT
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Brain midline-shift measurement on adult non-contrast CT
Evidence takeaway. Evidence from the reviewed source record: Standalone validation used 153 NCCT cases from 13 sites (11 US, 2 outside US), ages 26-93, compared with three-expert reference. FDA-reported Rapid MAE was 0.7 mm versus expert average pairwise MAE 1.0 mm. Test cases were separate from development data.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Measurement-error evaluation does not establish a diagnostic sensitivity for a binary clinical condition.
A diagnostic specificity was not established by the reviewed measurement study.
0.7 mm
K243378
PMID:42481415 · doi:10.3174/ajnr.A9540
Abstract reports 0.8 mm MAE and tendency to underestimate shifts greater than 10 mm. Not substituted for FDA 0.7 mm result. Cohort may overlap regulatory data; not counted as independent replication.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: DICOM non-contrast head CT in adults
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-05 · Rapid MLS: K243378 decision and 510(k) summary
Source context, not route validation: NCCT processing module within Rapid Platform, with command-line interface and DICOM/JSON outputs
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-06 · Rapid MLS: K243378 decision and 510(k) summary
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Source context, not route validation: Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-06 · Rapid MLS: K243378 decision and 510(k) summary
Unresolved route: Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-06 · Rapid MLS: K243378 decision and 510(k) summary
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.
Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.
RapidAI's hemorrhagic-care page specifically describes Rapid MLS measurement and visualization
product family · checked 2026-09-05Other modules' hemorrhage volume, triage and reimbursement claims are not attributed to MLS.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
NCCT only for this module; the controlled CT/CTA category does not imply CTA input.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Stored PubMed candidate and live abstract reviewed; retained as family evidence with uncertain version and possible regulatory cohort overlap. Stored trial array empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Exact-name price/procurement search did not yield a reviewed primary-source module quote; platform bundle costs remain unestablished.
Bounded web search on 2026-10-26 (query: "Rapid CTA 360 RapidAI reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. RapidAI's reimbursement page lists NTAP for Rapid LVO (FY2021-2022 rules); it does not name this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
End-user onboarding, large-shift review guidance and local competency requirements remain unestablished.
11 sources - 3 history items
Scope: identity, clinical, evidence, implementation
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, clinical, evidence, implementation
Scope: implementation
Scope: evidenceStudies
Scope: vendorWideSecurity, deployment, implementationCapabilities
Scope: security, monitoring
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Brainomix Limited
Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.
iSchemaView
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Viz.ai, Inc.
Authorized purpose: Viz Subdural+ labels, visualizes, and quantifies subdural collections from single-time-point non-contrast head CT, reporting collection grayscale value, total volume, widest width, and midline shift as annotated DICOM images for physician review with original CT.
Brainomix Limited
Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history